Cambridge Investment Research Advisors
MDCO

Cambridge Investment Research Advisors’s Medicines Co MDCO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-39,166
Closed -$1.43M – 2441
2019
Q2 		$1.43M Buy
+39,166
New +$1.28M 0.01% 861

Other funds holding MDCO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Cambridge Investment Research Advisors's MDCO Position: Q3 2019 in Review

Cambridge Investment Research Advisors sold out of Medicines Co (MDCO) in Q3 2019, closing a stake of 39,166 shares — an estimated $1.43M sold.

Cambridge Investment Research Advisors first reported a position in MDCO in Q2 2019 and held it in 1 quarter. The position peaked at $1.43M in Q2 2019. 250 funds tracked by Wall St. Rank hold MDCO as of Q3 2019.

  • Cambridge Investment Research Advisors reported no remaining Medicines Co position as of Q3 2019 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 39,166 Medicines Co shares in Q3 2019, an estimated $1.43M.
  • Cambridge Investment Research Advisors first reported a position in Medicines Co in Q2 2019 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Medicines Co position peaked at $1.43M in Q2 2019.
  • 250 funds tracked by Wall St. Rank held Medicines Co as of Q3 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2019, filed 28 Oct 2019.